These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 26022947)
1. Efficacy of an inhaled corticosteroid/long-acting β2-agonist combination in symptomatic COPD patients in GOLD groups B and D. Anzueto A; Jenkins CR; Make BJ; Lindberg M; Calverley PM; Fagerås M; Postma DS; Rennard SI; Tashkin DP Eur Respir J; 2015 Jul; 46(1):255-8. PubMed ID: 26022947 [No Abstract] [Full Text] [Related]
2. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Trudo F; Kern DM; Davis JR; Tunceli O; Zhou S; Graham EL; Strange C; Williams SA Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101 [TBL] [Abstract][Full Text] [Related]
3. Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. Morgan AR; Parker GJ; Roberts C; Buonaccorsi GA; Maguire NC; Hubbard Cristinacce PL; Singh D; Vestbo J; Bjermer L; Jögi J; Taib Z; Sarv J; Bruijnzeel PL; Olsson LE; Bondesson E; Nihlén U; McGrath DM; Young SS; Waterton JC; Nordenmark LH Eur J Radiol; 2014 Nov; 83(11):2093-101. PubMed ID: 25176287 [TBL] [Abstract][Full Text] [Related]
4. POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV Chalmers JD Chest; 2018 Apr; 153(4):778-782. PubMed ID: 29474807 [No Abstract] [Full Text] [Related]
5. COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV Pavord ID Chest; 2018 Apr; 153(4):782-784. PubMed ID: 29410364 [No Abstract] [Full Text] [Related]
6. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860 [TBL] [Abstract][Full Text] [Related]
7. Glycopyrrolate/formoterol (Bevespi Aerosphere) for COPD. Med Lett Drugs Ther; 2016 Oct; 58(1505):130-132. PubMed ID: 27701364 [No Abstract] [Full Text] [Related]
9. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. Mahler DA; Waterman LA; Ward J; Gifford AH J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045 [TBL] [Abstract][Full Text] [Related]
12. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial. Bölükbas S; Eberlein M; Eckhoff J; Schirren J Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351 [TBL] [Abstract][Full Text] [Related]
13. Nebulized arformoterol: what is its place in the management of COPD? Miles MC; Donohue JF; Ohar JA Ther Adv Respir Dis; 2013 Apr; 7(2):81-6. PubMed ID: 23147985 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment. Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120 [TBL] [Abstract][Full Text] [Related]
15. [Combined inhaled corticosteroid and long-acting beta-2-agonist in one inhaler in the treatment of chronic obstructive pulmonary disease]. Pedersen ST Ugeskr Laeger; 2005 Jun; 167(23):2504-6. PubMed ID: 16008004 [No Abstract] [Full Text] [Related]
16. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). Cecere LM; Slatore CG; Uman JE; Evans LE; Udris EM; Bryson CL; Au DH COPD; 2012 Jun; 9(3):251-8. PubMed ID: 22497533 [TBL] [Abstract][Full Text] [Related]
17. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease. Babu KS; Morjaria JB Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881 [TBL] [Abstract][Full Text] [Related]
18. Adherence to GOLD guideline treatment recommendations among pulmonologists in Turkey. Sen E; Guclu SZ; Kibar I; Ocal U; Yilmaz V; Celik O; Cimen F; Topcu F; Orhun M; Tereci H; Konya A; Ar I; Saryal S Int J Chron Obstruct Pulmon Dis; 2015; 10():2657-63. PubMed ID: 26715844 [TBL] [Abstract][Full Text] [Related]
19. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Cazzola M; Santus P; Di Marco F; Carlucci P; Mondoni M; Matera MG; Centanni S Pulm Pharmacol Ther; 2004; 17(3):121-5. PubMed ID: 15123220 [TBL] [Abstract][Full Text] [Related]
20. A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting β2 agonist in the treatment of moderate-to-severe persistent asthma. Patel YA; Patel P; Bavadia H; Dave J; Tripathi CB J Postgrad Med; 2010; 56(4):270-4. PubMed ID: 20935397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]